181 related articles for article (PubMed ID: 37047318)
1. Clinical and Functional Characteristics of the E92K
Kondratyeva E; Melyanovskaya Y; Bulatenko N; Davydenko K; Filatova A; Efremova A; Skoblov M; Bukharova T; Sherman V; Voronkova A; Zhekaite E; Krasovskiy S; Amelina E; Petrova N; Polyakov A; Adyan T; Starinova M; Krasnova M; Vasilyev A; Makhnach O; Zinchenko R; Kutsev S; Gokdemir Y; Karadag B; Goldshtein D
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047318
[TBL] [Abstract][Full Text] [Related]
2. Health Characteristics of Patients with Cystic Fibrosis whose Genotype Includes a Variant of the Nucleotide Sequence c.3140-16T>A and Functional Analysis of this Variant.
Kondratyeva E; Bukharova T; Efremova A; Melyanovskaya Y; Bulatenko N; Davydenko K; Filatova A; Skoblov M; Krasovsky S; Petrova N; Polyakov A; Adyan T; Amelina E; Shadrina V; Zhekaite E; Zodbinova A; Chernyak A; Zinchenko R; Kutsev S; Goldshtein D
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34071719
[TBL] [Abstract][Full Text] [Related]
3. Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids.
de Poel E; Spelier S; Suen SWF; Kruisselbrink E; Graeber SY; Mall MA; Weersink EJM; van der Eerden MM; Koppelman GH; van der Ent CK; Beekman JM
J Cyst Fibros; 2022 Mar; 21(2):246-253. PubMed ID: 34666947
[TBL] [Abstract][Full Text] [Related]
4. Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis.
Ramalho AS; Fürstová E; Vonk AM; Ferrante M; Verfaillie C; Dupont L; Boon M; Proesmans M; Beekman JM; Sarouk I; Vazquez Cordero C; Vermeulen F; De Boeck K;
Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32747394
[TBL] [Abstract][Full Text] [Related]
5. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.
Dekkers JF; Berkers G; Kruisselbrink E; Vonk A; de Jonge HR; Janssens HM; Bronsveld I; van de Graaf EA; Nieuwenhuis EE; Houwen RH; Vleggaar FP; Escher JC; de Rijke YB; Majoor CJ; Heijerman HG; de Winter-de Groot KM; Clevers H; van der Ent CK; Beekman JM
Sci Transl Med; 2016 Jun; 8(344):344ra84. PubMed ID: 27334259
[TBL] [Abstract][Full Text] [Related]
6. Spectrum of CFTR mutations in Chechen cystic fibrosis patients: high frequency of c.1545_1546delTA (p.Tyr515X; 1677delTA) and c.274G>A (p.Glu92Lys, E92K) mutations in North Caucasus.
Petrova NV; Kashirskaya NY; Saydaeva DK; Polyakov AV; Adyan TA; Simonova OI; Gorinova YV; Kondratyeva EI; Sherman VD; Novoselova OG; Vasilyeva TA; Marakhonov AV; Macek M; Ginter EK; Zinchenko RA
BMC Med Genet; 2019 Mar; 20(1):44. PubMed ID: 30898088
[TBL] [Abstract][Full Text] [Related]
7. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
[TBL] [Abstract][Full Text] [Related]
8. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.
Lopes-Pacheco M; Silva IAL; Turner MJ; Carlile GW; Sondo E; Thomas DY; Pedemonte N; Hanrahan JW; Amaral MD
Biochem Pharmacol; 2020 Oct; 180():114133. PubMed ID: 32628927
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Complex p.[Leu467Phe;Phe508del] CFTR Allele in the Intestinal Organoids Model: Implications for Therapy.
Kondratyeva E; Efremova A; Melyanovskaya Y; Voronkova A; Polyakov A; Bulatenko N; Adyan T; Sherman V; Kovalskaia V; Petrova N; Starinova M; Bukharova T; Kutsev S; Goldshtein D
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142302
[TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
12. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
13. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
[TBL] [Abstract][Full Text] [Related]
14. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
15. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
16. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
[TBL] [Abstract][Full Text] [Related]
17. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic Variants and Genotypes of the
Chernykh V; Krasovsky S; Solovova O; Adyan T; Stepanova A; Marnat E; Shtaut M; Sedova A; Sorokina T; Beskorovainaya T; Kondratyeva E; Shchagina O; Polyakov A
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003474
[TBL] [Abstract][Full Text] [Related]
19. Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.
Dekkers JF; Van Mourik P; Vonk AM; Kruisselbrink E; Berkers G; de Winter-de Groot KM; Janssens HM; Bronsveld I; van der Ent CK; de Jonge HR; Beekman JM
J Cyst Fibros; 2016 Sep; 15(5):568-78. PubMed ID: 27160424
[TBL] [Abstract][Full Text] [Related]
20. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.
Mutyam V; Sharma J; Li Y; Peng N; Chen J; Tang LP; Falk Libby E; Singh AK; Conrath K; Rowe SM
Am J Respir Cell Mol Biol; 2021 May; 64(5):604-616. PubMed ID: 33616476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
